Halozyme Therapeutics Cash Flow from Investing Activities 2010-2025 | HALO
Halozyme Therapeutics cash flow from investing activities for the twelve months ending March 31, 2025 was $-0.770B, a 181.69% increase year-over-year.
- Halozyme Therapeutics annual cash flow from investing activities for 2024 was $-0.263B, a 171.1% increase from 2023.
- Halozyme Therapeutics annual cash flow from investing activities for 2023 was $-0.097B, a 80.1% decline from 2022.
- Halozyme Therapeutics annual cash flow from investing activities for 2022 was $-0.487B, a 19.87% increase from 2021.